The company trades intellectual property rights for films, primarily buying and selling movie distribution rights to television and digital platforms.
The company lacks a durable competitive advantage, as evidenced by its inability to generate consistent revenue from operations. Financial performance is almost entirely dependent on the mark-to-market revaluation of mutual fund holdings rather than core business activities.
Capital is largely stagnant, sitting in mutual funds to generate 'other income' that covers administrative overhead. There is no evidence of productive reinvestment in the core business, and the company's subsidiary, Bama Infotech, is chronically loss-making with negative net worth.
The investment collapsed as the market finally stopped valuing the company as a going concern and began treating it as a decaying pool of stagnant capital. Over five years, the administrative overhead and losses from the Bama Infotech subsidiary slowly bled the mutual fund reserves dry. Without a functional core business to generate cash, the 'other income' became insufficient to cover rising compliance and operational costs. The lack of promoter skin in the game led to total apathy toward minority shareholders, and the stock price eventually converged with the shrinking liquidation value of its remaining financial assets.
RichFakir rates Universal Arts Ltd's business quality as poor — 11/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Universal Arts Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Universal Arts Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Universal Arts Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →